Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer

Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10% was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2%) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5%) were p53- positive (p53+), and 301 (42.5%) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95% confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients.

Original languageEnglish
JournalKaohsiung Journal of Medical Sciences
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Triple Negative Breast Neoplasms
Adjuvant Chemotherapy
Survival
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Mutation
p53 Genes
Multivariate Analysis
Confidence Intervals
Staining and Labeling
Incidence

Keywords

  • Chemotherapy
  • Immunohistochemistry
  • p53
  • Survival
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer. / Bae, Soo Youn; Jung, Seung Pil; Lee, Se Kyung; Yu, Jonghan; Lee, Jeong Eon; Kim, Seok Won; Nam, Seok Jin.

In: Kaohsiung Journal of Medical Sciences, 01.01.2018.

Research output: Contribution to journalArticle

@article{c2a1eabd1d304f1ba4c3fec94540fccf,
title = "Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer",
abstract = "Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88{\%} cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10{\%} was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2{\%}) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5{\%}) were p53- positive (p53+), and 301 (42.5{\%}) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95{\%} confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients.",
keywords = "Chemotherapy, Immunohistochemistry, p53, Survival, Triple-negative breast cancer",
author = "Bae, {Soo Youn} and Jung, {Seung Pil} and Lee, {Se Kyung} and Jonghan Yu and Lee, {Jeong Eon} and Kim, {Seok Won} and Nam, {Seok Jin}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.kjms.2018.07.003",
language = "English",
journal = "Kaohsiung Journal of Medical Sciences",
issn = "1607-551X",
publisher = "Elsevier (Singapore) Pte Ltd",

}

TY - JOUR

T1 - Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer

AU - Bae, Soo Youn

AU - Jung, Seung Pil

AU - Lee, Se Kyung

AU - Yu, Jonghan

AU - Lee, Jeong Eon

AU - Kim, Seok Won

AU - Nam, Seok Jin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10% was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2%) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5%) were p53- positive (p53+), and 301 (42.5%) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95% confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients.

AB - Mutations of the p53 gene are the most common genomic alterations associated with triple-negative breast cancer (TNBC) and are reported in 60–88% cases. Despite the high incidence of such mutations, there is no consensus about the clinical application of p53 detection in breast cancer management. This study investigates the prognostic value of immunohistochemically detected p53 in TNBC patients who received adjuvant chemotherapy. We reviewed the clinicopathologic features of 1088 TNBC patients who received curative surgery and adjuvant chemotherapy. Immunohistochemically, nuclear staining of >10% was defined as p53 “positive.” Of the total 1088 TNBC patients, 709 (65.2%) had no lymph node metastasis (N0). Among the N0 patients, 408 (57.5%) were p53- positive (p53+), and 301 (42.5%) were p53- negative (p53-). p53 + tumors showed a tendency for better breast cancer-specific survival (BCSS, p = 0.052) and overall survival (OS, p = 0.079) compared to p53- tumors. In multivariate analysis, p53 + tumors showed significantly better BCSS (p53 + vs. p53-; HR 2.8, 95% confidence interval: 1.1–7.3, p = 0.034); however, in TNBC patients with lymph node metastasis, there was no correlation between p53 status, clinicopathologic characteristics, and survival. Consequently, in TNBC patients who received adjuvant chemotherapy, immunohistochemical p53 expression was associated with better BCSS in N0 patients.

KW - Chemotherapy

KW - Immunohistochemistry

KW - p53

KW - Survival

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85052124305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052124305&partnerID=8YFLogxK

U2 - 10.1016/j.kjms.2018.07.003

DO - 10.1016/j.kjms.2018.07.003

M3 - Article

C2 - 30527200

AN - SCOPUS:85052124305

JO - Kaohsiung Journal of Medical Sciences

JF - Kaohsiung Journal of Medical Sciences

SN - 1607-551X

ER -